During a speech in the Senate, US Senator Dick Durbin criticized the FDA for delaying completion of the public health review of tobacco product applications (PMTA) prior to the launch of electronic cigarettes. The deadline for the FDA to complete review of e-cigarette applications was over eight months ago on September 9th, 2021.
The FDA announced on June 13th that it has filed the latest update on its review of electronic cigarette applications, stating that the review process will not be completed until July 2023. Products currently under review may still be available for sale.
These companies are saturating the market with addictive devices. Companies like Juul, which are partially owned by tobacco companies, understand that they are marketing their products to children," said Durbin during a press conference in his office. "For years, these products haven't been authorized by law. Who should regulate them? The FDA, but currently, there is no regulation.
In March of this year, Senator Durbin and 14 of his colleagues wrote a bipartisan letter calling on the FDA to immediately complete its review of e-cigarettes and reject any applications, particularly those with flavors marketed to children, that do not prove to be beneficial for public health. The letter also urged the removal of all unapproved e-cigarettes from the market.
Senator Durbin stated, "I urge the FDA to immediately put an end to their enforcement discretionary power and remove all unauthorized e-cigarettes from the market. Let's not let Juul and other tobacco companies continue to endanger our children for another day. Let's not cower in front of high-paid tobacco lawyers again.
Source: Tobacco Reporter
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
